Arvinas uses a proprietary PROTAC discovery engine to design bifunctional molecules that recruit E3 ubiquitin ligases and trigger proteasomal degradation of disease‑relevant proteins, expanding the druggable proteome for oncology and neurodegenerative indications. The company advances clinical‑stage degraders and offers partnership models for pharmaceutical and biotechnology companies to co‑develop or license these targeted protein‑degradation therapeutics.
Funding
Funding not disclosed
+1Founders
Product
Problem
Many disease-driving proteins lack suitable binding pockets for conventional small‑molecule inhibitors, leaving patients with serious cancers and neurodegenerative disorders without effective therapeutic options. Traditional drug discovery pipelines are constrained to modulation rather than elimination of these targets, resulting in high attrition rates and limited treatment options.
Solution
Arvinas leverages its proprietary PROTAC (Proteolysis‑Targeting Chimera) discovery engine to design bifunctional molecules that recruit an intracellular ubiquitin‑ligase to a disease‑relevant protein, triggering selective proteasomal degradation. By converting an undruggable target into a degradable substrate, the platform expands the druggable proteome and enables the creation of novel therapeutic candidates for oncology and neurology. The company advances multiple clinical‑stage programs that demonstrate the ability to achieve durable target knockdown, improved pharmacodynamics, and differentiated efficacy profiles compared with traditional inhibitors. Arvinas also partners with external pharmaceutical and academic groups to accelerate the translation of PROTAC chemistry into late‑stage development, providing a scalable route to new treatment options for patients with high unmet need.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to expand their pipeline with next‑generation modalities, as well as clinical researchers focused on oncology and neurodegenerative disease therapeutics.
Features
- Proprietary PROTAC discovery engine integrating structure‑based design, high‑throughput synthesis, and cellular degradation assays to rapidly generate candidate degraders.
- Modular chemistry platform that links ligands for E3 ligases (e.g., VHL, CRBN) with disease‑specific binders, enabling programmable selectivity across diverse protein families.
- Integrated pharmacokinetic and pharmacodynamic modeling pipeline to optimize linker composition, cellular permeability, and in‑vivo stability.
- Clinical‑stage pipeline including ARV‑471 (estrogen‑receptor degrader) and neurology programs targeting pathogenic transcription factors and kinases.
- Robust partnership framework offering co‑development, licensing, and joint‑venture models with large pharma and biotech collaborators.
- Comprehensive preclinical validation suite encompassing proteomics, biomarker identification, and in‑vivo efficacy studies to de‑risk translational progression.
- Compliance‑ready data management system supporting IND filing, regulatory submissions, and GxP documentation.